ARA-290RA10

Images are illustrative. Actual specifications are as selected and confirmed in writing.

Repair & Recovery Research

ARA-290

Small-fiber neuropathy and nerve repair

ARA-290 specifications and reference prices. Select a specification to add it to your cart.

10mg/vial x 10vials
Reference priceUS$160.61

For laboratory research only. Not for human or veterinary use.

COA 检测报告 / Reports

Compare all specifications & reference prices
SKUSpecification / packReference price (USD)
RA1010mg/vial x 10vialsUS$160.61
RA1616mg/vial x 10vialsUS$227.27

Temporarily sold-out specifications can still be added to an inquiry to ask about restocking. An inquiry is not an order or an agreed price.

RESEARCH FOCUS

Main Uses & FAQs

This page organizes directly relevant information on ARA-290 regarding small fiber neuropathy and nerve repair. First, review the research questions and findings, then verify the population or species, study formulations, and scope of interpretation.

Main TopicsSmall fiber neuropathy · Nerve repair
USAGE REFERENCE

ARA-290 · Usage reference (for research purposes)

The following presents common research-context references for reconstitution, storage, dosage and cycles. The following presents common references in research settings. This page does not constitute advice for use in humans or animals.

🧪Reconstitution

Suggested Diluent
Bacteriostatic Water (containing 0.9% benzyl alcohol); some peptides may use sterile water or acetic acid to aid dissolution. See the individual product descriptions.
Diluent Volume
Slowly introduce the diluent along the vial wall until the lyophilized powder is covered. A common example is 5 mg reconstituted with 2 mL of bacteriostatic water, yielding approximately 2.5 mg/mL. Referenced reconstitution volumes are approximately 1–2.5 mL, with 2 mL commonly used. It is suggested to select and record a fixed volume based on the COA supplied with the purchase.
Handling Notes
Introduce the diluent slowly along the vial wall rather than directly onto the lyophilized powder. Leave it for 60–90 seconds to dissolve naturally; do not shake vigorously.

💾Storage

Unreconstituted Lyophilized Powder
Refrigerate at 2–8°C, protected from light; avoid repeated freeze–thaw cycles.
After Reconstitution
Refrigerate at 2–8°C; a common recommendation is touse within 28 days; do not freeze.
Transport
For short periods, use insulated packaging with ice packs; avoid high temperatures and direct light.

📏Dosage Reference (Research)

Purpose / SettingCommon Reference
ExplanationNeurodegeneration repair research

Note: The above describes common research-context references, rather than clinical recommendations. Refer to the batch COA and research protocol. For research use only; not for human or animal use.

Research SummaryKey Findings

What research findings exist regarding ARA-290 in small fiber neuropathy and nerve repair?

ARA290 inhibits early inflammation and NLRP3-related activation and promotes functional recovery. Additionally, some studies report increased corneal and skin small nerve fiber indicators at certain dosage levels.[1] ↗ [2] ↗

Before ReadingStudy populations, species, formulations and delivery conditions each have a defined scope. Research on an ingredient does not establish that this site's product batches have been validated for efficacy in humans or veterinary use.
4 Main ReferencesSorted by First Publication Date ↓
Animal / experimental studies2025REF. 01

How are inflammation and functional recovery after sciatic nerve injury?

Research Findings

ARA290 inhibits early inflammation and NLRP3-related activation and promotes functional recovery.[1] ↗

Study Design

Rat sciatic nerve crush model and Schwann cells

Scope & Limitations

Preclinical peripheral nerve injury, not equivalent to treatment effects in human small fiber neuropathy.

View the Article Title and Full Citation+

ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury.

Liu G, Li W, Jiang S, Liang J, Song M, Wang L, Wang X, Liu X, Yang Z, Zhang L, Yang Y, Zhang B

European Journal of Pharmacology · Volume and Issue Year 2025
First published 2025-04-09 · PMID 40216181
DOI 10.1016/j.ejphar.2025.177610

Human Study2017 · Historical basic researchREF. 02

Are nerve fiber structure and pain endpoints consistent?

Research Findings

Specific dosage group showed increased corneal and skin small nerve fiber indices.[2] ↗

Study Design

64 patients with sarcoidosis-related small fiber neuropathy; 28-day Phase IIb randomized trial.

Scope & Limitations

Nerve fibers used as surrogate endpoint; no significant pain group difference, cannot be claimed as proven pain relief.

View the Article Title and Full Citation+

Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.

Culver DA, Dahan A, Bajorunas D, Jeziorska M, van Velzen M, Aarts LPHJ, Tavee J, Tannemaat MR, Dunne AN, Kirk RI, Petropoulos IN, Cerami A, Malik RA, Brines M

Investigative Ophthalmology & Visual Science · Volume/Issue/Year 2017
First published 2017-05-01 · PMID 28475703
DOI 10.1167/iovs.16-21291

Human Study2015 · Historical basic researchREF. 03

What has been observed in studies of diabetic neuropathy?

Research Findings

Improvement of neurodegenerative symptoms and some metabolic indicators, increased corneal nerve fiber metrics in some patients.[3] ↗

Study Design

Type 2 diabetes with neuropathy; 28 days ARA290 or placebo, 56 days follow-up

Scope & Limitations

Small Phase II studies, targeted populations, and short follow-up; Not equivalent to general neuroregeneration commitments.

View the Article Title and Full Citation+

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A

Molecular medicine (Cambridge, Mass.) · Volume/Issue Year 2015
First published on 2015-03-13 · PMID 25387363
DOI 10.2119/molmed.2014.00215

Human Study2013 · Historical basic researchREF. 04

What research clues are there for sarcoidosis-related neurological symptoms?

Research Findings

Improvement in neurological symptoms, corneal nerve fiber density, and some motor function indicators.[4] ↗

Study Design

Nodular small fiber neuropathy; 28-day blinded placebo-controlled study

Scope & Limitations

Historical small-sample studies cannot be described as general neural repair or cure.

View the Article Title and Full Citation+

ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.

Dahan A, Dunne A, Swartjes M, Proto PL, Heij L, Vogels O, van Velzen M, Sarton E, Niesters M, Tannemaat MR, Cerami A, Brines M

Molecular medicine (Cambridge, Mass.) · Volume/Issue Year 2013
First published on 2013-11-08 · PMID 24136731
DOI 10.2119/molmed.2013.00122

i

Currently, 4 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.

GO DEEPER

What Questions Do These Studies Address?

Compare study populations, findings and scope.

↗
QUESTIONS, ANSWERED

ARA-290 · Frequently Asked Questions.

What research findings exist regarding ARA-290 in small fiber neuropathy and nerve repair?+

ARA290 inhibits early inflammation and NLRP3-related activation and promotes functional recovery. Additionally, some studies report increased corneal and skin small nerve fiber indicators at certain dosage levels.[1] ↗ [2] ↗

Does an increase in nerve fibers from ARA-290 necessarily mean pain relief?+

Not equal. In a Phase IIb study, specific group corneal small nerve fiber indices increased, but the placebo-corrected differences in pain were not significant; structural indices and symptoms should be stated separately.[2] ↗

ARA-290—these conclusions apply to which study populations?+

Rat sciatic nerve crush model and Schwann cells; 64 patients with sarcoidosis-related small fiber neuropathy; 28-day Phase IIb randomized trial; type 2 diabetes with neuropathy; 28 days ARA290 or placebo, 56 days observation. Preclinical peripheral nerve injury, not equivalent to human small fiber neuropathy treatment effect.[1] ↗ [2] ↗ [3] ↗

VENTRO PEPTIDES & BIOTECH · RESEARCH PRODUCT RETAIL

Research peptides. Shop by product.

Compare specifications, reference prices and COA reports. Add products to your cart to request a quote.

Ventro Peptides & Biotech Logo
QUALITY DOCUMENTSCOA BY PRODUCTGLOBAL DELIVERYTECHNICAL SUPPORT

01 / CATALOG

Browse products

7 products Product names, specifications, and prices follow the current quotation
SemaglutideSM10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Semaglutide

10mg/vial x 10vials

US$90.91
TirzepatideTR20COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Tirzepatide

20mg/vial x 10vials

US$160.61
RetatrutideRT10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Retatrutide

10mg/vial x 10vials

US$109.09
BPC157BC10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

Repair & Recovery Research

BPC157

10mg/vial x 10vials

US$133.33
MOTS-CMS20COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

Longevity & Mitochondrial Research

MOTS-C

20mg/vial x 10vials

US$257.58
LiraglutideLR10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Liraglutide

10mg*10vials

US$164.71
IGF-lr3IG1COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

Growth Hormone & IGF-1

IGF-lr3

1mg/vial x 10vials

US$505.88

03 / ABOUT VENTRO

Reliable peptide supply, built for long-term partnerships.

Ventro supports research product retail purchases with clear pack specifications, available quality documents, and responsive international support.

  • High-purity peptides
  • Available COA reports
  • COA & quality documentation
  • Flexible small-quantity purchases
  • Reliable global fulfillment
  • Research product retail support

04 / QUALITY SYSTEM

Quality without compromise

Browse the available COA reports by product. Confirm documentation for your order with our team.

Controlled quality workflowRaw material to final release
Responsive global supportProduct matching and technical support

RESEARCH PRODUCT INQUIRY

Submit a product inquiry

Tell us the product, specification, and expected quantity. Our team will respond with pricing and available documents.

Use another email app

Opening an inquiry creates a draft, not a sent message. Review and press Send in Gmail, WhatsApp or your email app. Opening a channel passes the draft to the chosen provider. Privacy & cookies

Contact Ventro

Choose a channel to contact the Ventro team directly.

Use another email app

Opening an inquiry creates a draft, not a sent message. Review and press Send in Gmail, WhatsApp or your email app. Opening a channel passes the draft to the chosen provider. Privacy & cookies

WhatsApp